Answers are grounded in this paper and cite their sources.
The rising incidence of superficial basal cell carcinoma (sBCC) puts a large burden on healthcare budgets worldwide. There are several treatment options for sBCC with difference in terms of effectiveness and costs. A few studies examined the cost-effectiveness of treatments for sBCC. We performed a systematic review following the PRISMA guidelines to determine the number and quality of the existing economic evaluations of treatment options for sBCC from a healthcare perspective. Our search of OVID Medline, Embase, Cochrane, and the NHS Economic Evaluation Database included all economic evaluations of any treatment for sBCC. Non-original articles, articles on high-risk BCC, and articles concerning Mohs surgery, radiotherapy, or systemic treatment were excluded. Risk of bias was evaluated using the extended version of the Consensus on Health Economic Criteria. The search was performed in February 2023, yielded 710 records and resulted in the inclusion of 4 economic evaluations. Two were trial-based economic evaluations and two were decision analytical models. Costs and effects were compared for imiquimod and 5FU versus MAL-PDT, imiquimod versus surgery, and MAL-PDT versus surgery. Due to heterogeneity, the results could not be pooled. The quality of the studies was moderate to high. One of the issues was that uncertainty around the given Incremental Costs and Effects Ratios was not or insufficiently addressed. The conclusions of the authors could not be corroborated in all cases. In the end, we conclude that treatment of sBCC with imiquimod as well as surgery seemed to provide value for money. Compared to treatment with imiquimod, MAL-PDT did not provide value for money.
No takes yet. Share an insight, caveat, or question.
Delft et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: